Medtronic (NYSE:MDT – Get Free Report) updated its FY 2025 earnings guidance on Sunday. The company provided earnings per share (EPS) guidance of 5.420-5.500 for the period, compared to the consensus estimate of 5.440. The company issued revenue guidance of $33.5 billion-$33.8 billion, compared to the consensus revenue estimate of $33.4 billion.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on MDT. Citigroup dropped their price objective on shares of Medtronic from $90.00 to $85.00 and set a neutral rating for the company in a research report on Wednesday, July 10th. Daiwa America upgraded shares of Medtronic to a strong-buy rating in a research report on Friday, August 23rd. Piper Sandler increased their price target on shares of Medtronic from $85.00 to $90.00 and gave the company a neutral rating in a research report on Wednesday, August 21st. The Goldman Sachs Group started coverage on shares of Medtronic in a research note on Thursday, May 30th. They issued a sell rating and a $83.00 target price for the company. Finally, Truist Financial boosted their price target on shares of Medtronic from $85.00 to $90.00 and gave the company a hold rating in a report on Friday, August 23rd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of Hold and a consensus price target of $92.92.
Get Our Latest Research Report on MDT
Medtronic Stock Performance
Medtronic (NYSE:MDT – Get Free Report) last posted its earnings results on Tuesday, August 20th. The medical technology company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. Medtronic had a return on equity of 13.68% and a net margin of 12.06%. The business had revenue of $7.97 billion for the quarter, compared to analyst estimates of $7.90 billion. During the same period in the previous year, the firm earned $1.20 EPS. The firm’s revenue was up 3.4% compared to the same quarter last year. As a group, equities analysts forecast that Medtronic will post 5.46 earnings per share for the current year.
Medtronic Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 11th. Stockholders of record on Friday, September 27th will be given a $0.70 dividend. The ex-dividend date is Friday, September 27th. This represents a $2.80 dividend on an annualized basis and a dividend yield of 3.16%. Medtronic’s payout ratio is presently 101.82%.
Insiders Place Their Bets
In other news, CEO Geoffrey Martha sold 19,113 shares of the stock in a transaction on Friday, June 7th. The stock was sold at an average price of $83.77, for a total transaction of $1,601,096.01. Following the sale, the chief executive officer now directly owns 143,348 shares of the company’s stock, valued at approximately $12,008,261.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.30% of the company’s stock.
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
Further Reading
- Five stocks we like better than Medtronic
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Hidden Opportunities in Li Auto’s Tough Quarter You Can’t Miss
- What Are Dividend Champions? How to Invest in the Champions
- Don’t Overlook Campbell Soup: Here’s What Could Drive Its Stock
- Basic Materials Stocks Investing
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.